- Home
- FGF vs UBX Comparison
FGF vs UBX Comparison
Compare FGF & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGF
- UBX
- Stock Information
- Founded
- FGF 2012
- UBX 2009
- Country
- FGF United States
- UBX United States
- Employees
- FGF N/A
- UBX N/A
- Industry
- FGF Property-Casualty Insurers
- UBX Biotechnology: Pharmaceutical Preparations
- Sector
- FGF Finance
- UBX Health Care
- Exchange
- FGF Nasdaq
- UBX Nasdaq
- Market Cap
- FGF 20.9M
- UBX 13.9M
- IPO Year
- FGF N/A
- UBX 2018
- Fundamental
- Price
- FGF $16.01
- UBX $0.78
- Analyst Decision
- FGF
- UBX Strong Buy
- Analyst Count
- FGF 0
- UBX 3
- Target Price
- FGF N/A
- UBX $4.67
- AVG Volume (30 Days)
- FGF 3.5K
- UBX 609.1K
- Earning Date
- FGF 08-13-2025
- UBX 08-05-2025
- Dividend Yield
- FGF N/A
- UBX N/A
- EPS Growth
- FGF N/A
- UBX N/A
- EPS
- FGF N/A
- UBX N/A
- Revenue
- FGF $13,260,000.00
- UBX N/A
- Revenue This Year
- FGF N/A
- UBX N/A
- Revenue Next Year
- FGF N/A
- UBX N/A
- P/E Ratio
- FGF N/A
- UBX N/A
- Revenue Growth
- FGF N/A
- UBX N/A
- 52 Week Low
- FGF $14.21
- UBX $0.36
- 52 Week High
- FGF $38.40
- UBX $3.10
- Technical
- Relative Strength Index (RSI)
- FGF 37.21
- UBX 48.12
- Support Level
- FGF $16.50
- UBX $0.67
- Resistance Level
- FGF $18.87
- UBX $0.83
- Average True Range (ATR)
- FGF 0.47
- UBX 0.09
- MACD
- FGF -0.08
- UBX 0.01
- Stochastic Oscillator
- FGF 2.68
- UBX 24.67
About FGF FG Financial Group Inc. (NV)
Fundamental Global Inc through its subsidiaries operates as diversified insurance, reinsurance, and investment management holding company. The company's segments includes Insurance and Asset Management. It generates maximum revenue from the Insurance segment.
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.